Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury

See more here


Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic 

  • Melior’s therapeutic candidate, tolimidone, is:  
    • Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications 
    • A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies 

See more here


Renowned Nutrition Expert Puts Rare Disease Day on the Radar

Dr. Virginia A. Stallings Discusses Individualized Nutrition Therapy for People with Cystic Fibrosis  

See more here


Wellsheet Featured in KLAS Spotlight Targeting Physician Burnout

100% of Respondents Would Buy Wellsheet Again for Quick Access to Relevant Electronic Health Record Data to Reduce Time in the EHR 

See more here


Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

See more here


Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults

See more here


Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment

See more here


Annovis Bio’s Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study

See more here


ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab

ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint 

See more here


Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus

Findings support the potential of Immunome’s approach to developing IMM-BCP-01 as an optimized antibody cocktail for the treatment and prophylaxis of COVID-19  

See more here